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Abstract 
In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends 
annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to 
investigate the role of one-off non-contrast whole-body MRI (WB MRI) in the screening of asymptomatic TP53 
mutation carriers. 44 TP53 mutation carriers and 44 population controls were recruited. Scans were read by 
radiologists blinded to participant carrier status. The incidence of malignancies diagnosed in TP53 mutation 
carriers against general population controls was calculated. The incidences of non-malignant relevant disease 
and irrelevant disease were measured, as well as the number of investigations required to determine relevance of 
findings. In TP53 mutation carriers, six of 44 (13.6%, 95% CI: 5.2%-27.4%) participants were diagnosed with 
cancer during the study, all of which would be considered life threatening if untreated. Two were found to have 
two primary cancers. Two participants with cancer had abnormalities on the MRI which were initially thought to 
be benign (a pericardial cyst and a uterine fibroid) but transpired to be sarcomas. No controls were diagnosed 
with cancer. Fifteen carriers (34.1%, 95% CI: 20.5%-49.9%) and 7 controls (15.9%, 95% CI: 6.7%-30.1%) 
underwent further investigations following the WB MRI for abnormalities that transpired to be benign 
(p=0.049). The cancer detection rate in this group justifies a minimum baseline non-contrast WB MRI in 
germline TP53 mutation carriers. This should be adopted into national guidelines for management of adult TP53 
mutation carriers in addition to the current practice of contrast enhanced breast MRI imaging. 
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Introduction 
Li-Fraumeni Syndrome (LFS) is a rare autosomal dominant condition which predisposes individuals to 
numerous cancer types. The majority of families with LFS have been found to carry mutations in the TP53 gene 
[1-3]. Typical cancers in the Li-Fraumeni spectrum include soft tissue and bone sarcoma, breast, brain, adrenal 
cortical carcinoma and leukaemia[4], however an increased risk has also been found in many other cancer types 
[5, 6]. The cancers are typically young onset occurring two or three decades before the median in the general 
population [6], and individuals are predisposed to multiple malignancies [7]. The condition has a high 
penetrance, with a lifetime cancer risk of almost 100% for females and 75% for males [8] and may have a birth 
incidence as high as 1 in 5,000 [9]. 
In the United Kingdom, the National Institute for Health and Clinical Excellence (NICE) recommends annual 
breast MRI from age 20-49 years for female TP53 mutation carriers and to consider continuation of breast 
screening past age 50. Discussion of risk-reducing mastectomy is also recommended, however, no other 
surveillance is currently suggested in any guidelines. Screening across UK genetics centres varies and many 
employ an open-door policy for carriers experiencing symptoms. 
Recent evidence suggests there may be a survival benefit with more intensive screening, including whole-body 
MRI (WB MRI) [10, 11]. Internationally, more intensive screening programmes are starting to become 
employed [12, 13] and, in particular, are being explored in the research setting [10, 14-16]. Several studies are 
employing WB MRI [14, 17], others FDG-PET/CT [15, 16], and, most commonly, combinations of several 
physical examination, imaging and biochemical screening modalities [10, 14, 17]. Given the lack of radiation, 
WB MRI provides an attractive choice to screen this cohort of individuals with an increased susceptibility to 
radiation-induced neoplasms [18, 19]. 
When considering a screening modality, the incidence of incidental findings is important in decision making 
whether to adopt the modality in guidelines. To our knowledge, no studies have employed a healthy control 
group to compare the incidence of malignancies and incidental findings to that found in the TP53 mutation 
carriers. 
This pilot study aimed to assess the incidence of malignancies diagnosed in asymptomatic TP53 mutation 
carriers using a non-contrast WB MRI against general population controls, as well as the incidences of non-
malignant relevant and irrelevant disease and the investigations required to determine relevance. It was 
 6 
 
hypothesised that more malignancies would be diagnosed in the TP53 mutation carrier cohort than in the 
controls and the ratio of relevant to non-relevant findings (relevant defined as needing definitive treatment) 
would be higher in the TP53 mutation carriers than controls. 
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Methods 
Study Subjects and Data Collection 
From November 2012 through July 2016, TP53 mutation carriers were recruited through genetics services from 
across the United Kingdom and general population controls through local advertisements. Carriers with a known 
low penetrance TP53 mutation (in the view of a geneticist) or a variant of unknown significance were excluded, 
as well as those with a malignancy diagnosed in the previous five years (except non-melanomatous skin cancer 
or cervical carcinoma in situ (CIS)). Population controls were sex and age (+/- 5 years) matched to carriers and 
required to have no personal history of cancer (except non-melanomatous skin cancer or cervical CIS) and 
minimal family history of cancer (no first degree relative diagnosed before age 50 and only one first, second or 
third degree relative diagnosed at any age). Any person with current symptoms suggestive of malignancy was 
excluded. 
An additional sub-study was included to examine the psychosocial impact of screening in this group of high-risk 
individuals, the results of which will be reported separately. 
The research was approved by the Health Research Authority NRES Committee London – Brent (12/LO/0781). 
MRIs 
MRI examinations were performed at The Royal Marsden NHS Foundation Trust or Central Manchester 
University Hospitals NHS Foundation Trust using a 1.5Tesla MRI machine (Siemens, Erlangen, Germany) from 
vertex to feet using conventional MR imaging sequences (T1-weighted, with or without fat suppressed T2-
weighted/STIR sequences), as well as diffusion weighted images (Supplementary Table 1). Slices were 0.8cm 
thick and scans were not contrast enhanced. Comparisons of imaging techniques will be reported elsewhere. 
Scans were read independently by two radiologists with at least 5 years’ experience, who were blinded to the 
mutation status of the study participants. MRIs were divided into anatomical sections and each section scored 0 
to 5 (0 normal findings, 1 definitely benign, 2 likely to be benign, 3 equivocal, 4 likely to be malignant, 5 
definitely malignant). Initial recommendations for further investigations were made blinded to carrier status, 
however subsequent review and intervention was made with consideration of this factor. In a case of 
discrepancy a consensus reading was performed by the two study radiologists plus a radiologist from the other 
centre. Ten percent of scans, selected randomly, were cross-read at both centres for quality assurance. Lesions 
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requiring investigation and incidental findings were discussed in a cross centre video-linked multidisciplinary 
team (MDT) meeting including PIs, radiologists and other study staff from both sites. All pathology was 
reviewed by expert pathologists in two tertiary cancer centres and at tumour-specific multidisciplinary team 
meetings.  
Sample Size and Statistical Analysis 
A total of 88 participants were recruited to the study, with 44 carriers of TP53 mutations matched to 44 healthy 
population controls. This sample size was calculated for 80% power to detect a difference in cancer detection 
between the mutation carrier group and the control group assuming a 20% cancer detection rate in the carrier 
group and 1% in the control group for a two-tailed analysis. 
The efficacy of WB MRI as a screening tool was evaluated by diagnosis of early stage malignancy in 
asymptomatic individuals, with respect to the number of further investigations required and false positives. 
Incidence of malignancies with 95% confidence intervals was calculated in both carrier and control groups and 
any difference between groups was compared using chi-square or Fisher’s exact test as appropriate at a 5% 
significance level. The incidence of and proportion of the cohort with relevant and non-relevant MRI findings is 
reported with 95% confidence intervals. Of those who were recalled, additional investigations with non-
malignant results were reported with 95% confidence intervals and any difference between groups assessed 
using Mann-Whitney test. All statistical tests were two-sided and analysis was performed using STATA [20].  
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Results 
Patient characteristics 
Forty-four TP53 mutation carriers from 37 families and 44 matched healthy population controls were recruited 
(Table 1). Nine of the 27 female TP53 carriers had had risk-reducing surgery of some kind, or mastectomies for 
previous breast cancer. 
Cancer Diagnoses and Treatments 
In TP53 mutation carriers, six of 44 (13.6%, 95% CI 5.2%-27.4%) participants were diagnosed with cancer 
during the study (Table 2). Only four (9.1%, 95% CI 2.5%-21.7%) of these were a direct result of the study WB 
MRI, however two participants had two simultaneous primary tumours diagnosed. There was no diagnosis of 
cancer in the control group. Analysis showed no statistically significant difference in number of TP53 mutation 
carriers diagnosed with malignancy compared to controls (p=0.116), however the study was powered at a higher 
cancer detection rate in TP53 mutation carriers. 
All four individuals with screen detected cancers were women who were asymptomatic and all were treated with 
curative intent.  
The first woman had a low grade astrocytoma in the right inferior temporal gyrus and underwent a R0 resection 
with full post-operative recovery two years after surgery. Upon questioning after her diagnosis she 
retrospectively reported episodes of déjà vu but no other symptoms and had never had a cancer diagnosis 
previously. 
The second woman was diagnosed with a myxosarcoma in the abdominal wall (Trojani grade 2).  The size was 
46 x 37mm and all margins were free indicating complete surgical excision. She did not require additional 
chemotherapy or radiotherapy. This patient had a previous cancer history of ovarian teratoma at age 4, 
phylloides tumour of the breast aged 41 and DCIS breast cancer at 42 and a fibrosarcoma of the left thigh at 42. 
The third woman was 45 years of age and reported irregular menstrual cycle on enrolment. She had no history 
of cancer and was found to have a 10.6x8.6cm mass of the right kidney on WB MRI. The differential diagnosis 
included an oncocytoma or renal cell carcinoma. Additionally, two uterine fibroids and an ovarian cyst were 
detected. Following renal CT and pelvic MRI, she underwent a right nephrectomy and given her carrier status 
and age, simultaneous total abdominal hysterectomy, right salpingectomy (right ovary previously excised) and 
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left salpingo-oophorectomy. A 110mm chromophobe renal cell carcinoma (Fuhrman grade 3) confined to the 
kidney with no lymphovascular invasion was detected, plus an incidental benign renal angiomyolipoma 
measuring 15mm. In the resected uterus, 2 fibroids were present; the larger (65mm) was found to be a 
leiomyosarcoma confined to the myometrium with no evidence of vascular invasion, and the smaller 
(25mm) fibroid was a benign leiomyoma. The left ovary contained a benign cyst and interestingly both 
fallopian tube fimbrial ends were noted to contain scattered atypical epithelial cells with severe 
cytological atypia, thought to be more consistent with a tubal intra-epithelial lesion in transition rather 
than a definite serous intra-epithelial carcinoma. Both the uterine and renal tumour resections were R0 
and no further treatment was required.  
The fourth participant had previously had a rhabdomyosarcoma at 6 months of age. During the study, three 
tumours were detected, of which the first two (in the liver and right kidney) were detected on the initial WB 
MRI. Subsequent dedicated liver and renal MRIs were inconclusive but were strongly suspicious of malignancy. 
Resection of the lesions revealed epithelioid angiomyolipomas in both organs, with suspiciously high mitotic 
incidence, however their malignant potential was unclear, as was the synchronicity of the tumours. Given the 
rarity of angiomyolipomas, tuberous sclerosis was subsequently ruled out. While on follow up for these initial 
tumours, a new left sacroiliac lesion was detected 19 months after the initial WB MRI. This was initially 
monitored then biopsied, diagnosing a high-grade chondroblastic osteosarcoma. The patient has completed 
methotrexate, doxorubicin and cisplatin (MAP) chemotherapy; surgery has been advised but the patient is 
pursuing proton beam therapy in the USA. 
An additional patient had a pericardial cyst (seen on WB MRI) that was initially reported as likely benign but 
became symptomatic and non-study dedicated MRI and biopsy revealed a mediastinal sarcoma. The sixth was 
diagnosed with B-cell acute lymphocytic leukaemia nine months after his whole-body MRI. This patient’s WB 
MRI was negative and he only reported some upper abdominal discomfort when questioned on enrolment in the 
study. 
Non-Malignant Findings from WB MRI 
Outcomes of findings from the WB MRI are detailed in Table 2 with further details of all investigations in 
Supplementary Table 2. Fifteen carriers (34.1%, 95% CI: 20.5% to 49.9%) and 7 controls (15.9%, 95% CI: 
6.7% to 30.1%) underwent further investigations after their WB MRI that did not result in a diagnosis of cancer 
 11 
 
(Table 5). There was a marginally significant difference between the groups (p=0.049). Six carriers and one 
control had more than one follow-up investigation (Table 4). Of those who were recalled, TP53 mutation 
carriers on average had 2.33 (95% CI: 1.17 to 3.50) additional investigations with non-malignant results and 
controls 1.14 (95% CI: 0.79 to 1.49). There was no significant difference between groups (p=0.101). 
There was one case in a TP53 mutation carrier of a non-malignant incidental finding that needed intervention 
(triggering a rheumatology referral) and additionally three lesions in two TP53 mutation carriers are requiring 
continued surveillance given their genetic status (3 of 44, 6.8%; 95% CI: 1.4% to 18.7%). 
Eight investigations with non-malignant results (four CTs, two PET-CT scans and one X-ray) were carried out 
in five carriers using imaging techniques that exposed the participant to radiation (Table 5). However the 
majority of investigations conferred no exposure: most commonly, MRI imaging was used (13 scans in carriers 
and two in controls, either repeat scanning to monitor growth of the lesion, addition of contrast or more detailed 
imaging), then ultrasound (eight scans in carriers and six in controls). Two invasive procedures that did not 
result in a diagnosis of cancer were undertaken in carriers in the study: a biopsy of a suspicious pelvic bone 
lesion and the simultaneous salpingo-oophorectomy (for likely ovarian cyst) with nephrectomy and 
hysterectomy in the case of the chromophobe renal cell cancer. 
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Discussion 
The SIGNIFY baseline WB MRI study demonstrates an overall cancer detection rate of 9.1% in prevalent WB 
MRI scans in TP53 mutation carriers with no cancers identified in controls (p=0.116). The peak annual 
incidence rate for malignancy in TP53 mutation carriers is around 3% [21] therefore the prevalence in study of 
9.1% suggests there is significant lead time in the cancers detected which indicates that such screening is likely 
to be effective in LFS. This would be further demonstrated by a low detection rate at a subsequent annual 
incident screens which remains to be proven. Similar findings of a high prevalent detection rate was found in the 
MARIBS study [22, 23] (which included TP53 mutation carriers) with 2.7% of 632 women detected with breast 
cancer at prevalent screen dropping to 1.2% at the first incident round. This has translated into a significant 
survival benefit in women undergoing breast MRI screening [22]. 
The detection rate at prevalent screen could have been higher at 11.3% if further dedicated MRI had been 
performed as part of the study to detect the mediastinal sarcoma that had presented with a pericardial fluid 
collection that appeared to be a benign cyst. Additionally, the seemingly benign appearance of the uterine 
leiomyosarcoma also argues for a lower threshold for suspicion in this high risk cohort. Although, further 
investigation of these apparent benign features would lead to a higher rate of subsequent radiological 
investigation, this may translate into higher tumour survival rates. Complete resection of a brain astrocytoma, 
abdominal wall sarcoma and liver, kidney and uterine tumours may not have been possible without 
presymptomatic MRI detection in the current study. Sarcomas and brain malignancy in TP53 mutation carriers 
have poor overall survival rates and without curative surgery patients gain little benefit from chemotherapy or 
radiotherapy [24-26]. Indeed the avoidance of radiotherapy through complete surgical excision may well 
prevent future radiation induced malignancy that appears to be very high in TP53 mutation carriers [18]. It is 
likely that annual WB MRI [10, 11] will be required as sarcomas in TP53 mutation carriers are often high grade 
and one patient already developed an osteosarcoma 19 months after a true negative prevalent scan. 
Thus far if the missed mediastinal sarcoma and leukaemia are included, two symptomatic malignancies have 
developed in the 12-months post prevalent MRI. The leukaemia would not have been expected to be detected 
and further additional blood and other tests need to be considered in TP53 mutation carriers as occurs in the 
Toronto protocol [10, 11]. In particular we do not believe that WB MRI will replace dedicated breast MRI 
which requires a breast coil and gadolinium injection for the highest sensitivity [23]. This indicates that both 
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screening measures will be needed in the management of TP53 mutation carriers. It is not yet known how often 
such scans should be undertaken; at present breast MRI is performed annually from 20 to 50 years, but further 
studies are needed to assess if WB MRI needs to be repeated annually concurrently. 
There was a high rate of identification of incidental findings at WB MRI. More than twice as many TP53 
mutation carriers required further investigation for incidental findings, resulting in a marginally significant 
difference between the groups (p=0.049). Carriers who were recalled also had a higher number of repeat scans 
compared to controls, however this difference did not reach significance (p=0.110). We are awaiting the 
psychological outcomes of these in a study related protocol, but this high rate of investigation including eight 
TP53 mutation carriers versus zero controls requiring modalities involving radiation for further investigation is 
of concern. Nonetheless the higher rate of these findings may presage future malignancy risk as evidenced by 
the finding of apparent benign cystic lesions in the bone and pericardium that were found to be tumour related. 
This study only considered mutation carriers with mutations previously known to be of high penetrance and it is 
possible that the balance of incidental findings and relevant tumour detection may not be the same in those with 
low penetrance mutations, such as the Brazilian founder mutation [27]. The increase in use of gene panels in 
families or individuals with cancer without a history of classical LFS or LFL syndrome will identify more 
individuals with germline TP53 mutations where the penetrance may be lower and the role of WB MRI in such 
individuals is still uncertain.   
LFS leads to tumours in both children and adults, however it was not possible to examine the role of screening 
children in the present study as the Ethics Committee passed the protocol to be undertaken in adults only. 
Furthermore, studies from Toronto have published the use of screening in the paediatric age group [10,11]. 
The present study has some limitations. The study size was not sufficient to detect significant differences in 
tumour rates between cases and controls, but the trend of the data are compelling. Nonetheless the blinding of 
radiologists to cases and controls, the first time we are aware this has been done, is an obvious strength. In 
particular, the imaging of controls has demonstrated the incidental finding incidence in a small general 
population cohort. It is interesting that the rate of recall for further scans was higher in mutation carriers and 
there are animal data that suggest that mutation carriers may have dysmorphic features [28, 29]. It would be 
ideal to undertake an international meta-analysis of WB MRI data in TP53 mutation carriers 
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The malignancy prevalence of 13.6% in this study, detection rate on initial MRI of 9.1% and two cases of 
simultaneous primary cancers in two participants all argue for the adoption of at least a baseline whole body 
MRI scan in the screening of TP53 mutation carriers. Given the rarity of this condition and the relative ease of 
delivery of MRI without contrast, this additional screen warrants further research prior to incorporation into 
national guidelines for management of adult TP53 mutation carriers in addition to the current practice of 
gadolinium enhanced breast MRI imaging.  
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Tables 
Table 1: Characteristics of the cases and controls with previous malignant tumours 
 Carriers Controls 
N 44 44 
Age, median (range) 38 (19-58) 38 (22-59) 
Female, n (%) 27 (61%) 27 (61%) 
Male, n (%) 17 (39%) 17 (39%) 
Previous diagnosis of cancer, n (%) 18 (41%) 0 
Breast 11*  
Sarcoma 6  
Melanoma 2  
Ovarian 1  
Wilms Tumour 1  
Cervical 1  
Adrenocortical carcinoma 1  
Teratoma 1  
History of multiple cancers, n (%) 6 (13.6%) 0 
*4 bilateral breast cancers; 2 phylloides tumours 
  
 16 
 
Table 2: WB MRI Outcomes 
 WB MRI Outcome Overall Carriers Controls 
Further 
investigations 
triggered by WB 
MRI 
Cancer Detected 
(true positives) 
4 4 0 
Eventual Benign Outcome 
(false positives) 
16 9 7 
Requiring Continued Surveillance/ 
Treatment (non-malignant) 
3 3 0 
No further 
investigations 
triggered by WB 
MRI 
NAD 
(true negatives) 
63 26 37 
Subsequent Cancer Diagnosis 
(false negatives) 
2 2 0 
Total  88 44 44 
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Table 3: Cancer Diagnoses in Participants 
Pt Sex Age Mutation Abnormality (score) 
seen on WB MRI 
Further 
Investigations 
Cancer Treatment 
1 F 33 c.455C>T 
p.Pro152Leu 
Right temporal lobe cyst 
(4) 
Dedicated brain MRI 
with contrast 
Astrocytoma Complete resection 
2 F 51 c.659A>G 
p.Tyr220Cys 
Left lateral abdominal 
wall mass - probable 
sarcoma (4) 
US guided biopsy Myxosarcoma Complete resection 
3 F 45 c.586C>T 
p.Arg196Ter 
Suspicious right renal 
mass (4) 
Uterine fibroids (2) 
Abdominal CT, 
nephrectomy 
Pelvic MRI, TAH 
Chromophobe renal 
cell carcinoma 
Leiomyosarcoma 
Complete resection 
4 F 24 c.844C>T 
p.Arg282Trp 
Liver lesion, possible 
focal nodular hyperplasia 
or hepatic adenoma (3) 
Right kidney lesion, 
possible complex renal 
cyst or solid lesion (3) 
1. Dedicated renal 
and liver MRI with 
contrast. Suspected 
sarcomas, 
nephrectomy and 
partial hepatectomy 
2. Follow-up pelvic 
MRIs for EAMLs 
detected progressive 
changes in sacro-iliac 
joint 
1. Renal EAML 
Liver EAML 
2. Sacro-iliac 
osteosarcoma 
3. Complete 
resection of both 
tumours 
1. MAP 
chemotherapy 
completed; surgery 
advised but patient 
pursuing proton beam 
therapy in USA. 
5 F 48 c.916C>T 
p.Arg306Ter 
Pericardial cyst (1) Nil 
Non study MRI and 
PET revealed a 
12.6cm hilar mass 
with small left pleural 
Mediastinal 
liposarcoma grade 3 
Resection with 
microscopic positive 
margins (0/8 lymph 
nodes involved) and 
chemotherapy 
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effusion 
6 M 27 c.818G>A 
p.Arg273His 
Nil N/A Diagnosed with B 
ALL (not seen on WB 
MRI) 
Chemotherapy 
EAML = Epithelioid angiomyolipoma; MAP = methotrexate, doxorubicin and cisplatin; TAH = total abdominal 
hysterectomy 
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Table 4: Multiple Investigations after WB MRI with Non-Malignant Results 
 Total Number 
Additional 
Investigations 
1 investigation 
(n) 
2 investigations 
(n) 
3 investigations 
(n) 
≥4 investigations 
(n) 
Carriers 
(n=15) 
35 9* 1 1 4 
Controls 
(n=7) 
8 6 1 0 0 
*Including 2 TP53 mutation carriers diagnosed with cancer and additional incidental findings requiring 
investigations 
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Table 5: Number and Type of Follow up Investigations with Non-Malignant Results 
 Overall (n=22) Carriers (n=15)* Controls (n=7) 
Total investigations 43 35 8 
Radiation positive imaging 8 8 0 
Other imaging 29** 21* 8 
Biopsy/removal before definitive 
diagnosis 
2 2* 0 
Other investigations 4 4* 0 
*Including investigations for non-malignant findings in three TP53 mutation carriers with eventual cancer 
diagnoses 
**Three scans are pending results (two TP53 mutation carriers and one control) 
  
 21 
 
References 
1. Varley JM, McGown G, Thorncroft M, et al. (1997) Germ-line mutations of TP53 in Li-Fraumeni 
families: an extended study of 39 families. Cancer Res 57(15): 3245-52  
2. Varley JM (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21(3): 313-20 
DOI 10.1002/humu.10185 
3. Malkin D, Li FP, Strong LC, et al. (1990) Germ line p53 mutations in a familial syndrome of breast 
cancer, sarcomas, and other neoplasms. Science 250(4985): 1233-8  
4. Li FP, Fraumeni JF, Jr. (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial 
syndrome? Ann Intern Med 71(4): 747-52  
5. Gonzalez KD, Noltner KA, Buzin CH, et al. (2009) Beyond Li Fraumeni Syndrome: clinical 
characteristics of families with p53 germline mutations. J Clin Oncol 27(8): 1250-6 DOI JCO.2008.16.6959 
[pii]/10.1200/JCO.2008.16.6959 [doi] 
6. Nichols KE, Malkin D, Garber JE, Fraumeni JF, Jr., Li FP (2001) Germ-line p53 mutations predispose 
to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10(2): 83-7  
7. Hisada M, Garber JE, Fung CY, Fraumeni JF, Jr., Li FP (1998) Multiple primary cancers in families 
with Li-Fraumeni syndrome. J Natl Cancer Inst 90(8): 606-11  
8. Mai PL, Best AF, Peters JA, et al. (2016) Risks of first and subsequent cancers among TP53 mutation 
carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer:  DOI 10.1002/cncr.30248 
9. Lalloo F, Varley J, Ellis D, et al. (2003) Prediction of pathogenic mutations in patients with early-onset 
breast cancer by family history. Lancet (London, England) 361(9363): 1101-2 DOI 10.1016/s0140-
6736(03)12856-5 
10. Villani A, Shore A, Wasserman JD, et al. (2016) Biochemical and imaging surveillance in germline 
TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. 
The Lancet Oncology:  DOI 10.1016/S1470-2045(16)30249-2 
11. Villani A, Tabori U, Schiffman J, et al. (2011) Biochemical and imaging surveillance in germline TP53 
mutation carriers with Li-Fraumeni syndrome: a prospective observational study. The Lancet Oncology 12(6): 
559-67 DOI 10.1016/S1470-2045(11)70119-X 
12. Ballinger ML, Mitchell G, Thomas DM (2015) Surveillance recommendations for patients with 
germline TP53 mutations. Current opinion in oncology 27(4): 332-7 DOI 10.1097/CCO.0000000000000200 
13. McBride KA, Ballinger ML, Killick E, et al. (2014) Li-Fraumeni syndrome: cancer risk assessment and 
clinical management. Nat Rev Clin Oncol 11(5): 260-71 DOI 10.1038/nrclinonc.2014.41 
14. LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 
Mutation (Li-Fraumeni Syndrome) (LIFSCREEN) (2011),  
15. Masciari S, Van den Abbeele AD, Diller LR, et al. (2008) F18-fluorodeoxyglucose-positron emission 
tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 299(11): 1315-9 DOI 
299/11/1315 [pii]/10.1001/jama.299.11.1315 [doi] 
16. Nogueira STS, Lima ENP, Nóbrega AF, et al. (2015) (18)F-FDG PET-CT for Surveillance of Brazilian 
Patients with Li-Fraumeni Syndrome. Frontiers in Oncology 5: 38 DOI 10.3389/fonc.2015.00038 
17. A surveillance study investigating whole body magnetic resonance imaging and other diagnostic 
procedures in people at high risk of cancer (2013),  
18. Heymann S, Delaloge S, Rahal A, et al. (2010) Radio-induced malignancies after breast cancer 
postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 5: 104 DOI 1748-717X-5-104 
[pii]/10.1186/1748-717X-5-104 [doi] 
19. Evans DGR, Birch JM, Ramsden RT, Sharif S, Baser ME (2006) Malignant transformation and new 
primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone 
syndromes. Journal of Medical Genetics 43(4): 289-94 DOI 10.1136/jmg.2005.036319 
20. StataCorp (2015 ) Stata Statistical Software: Release 14. College Station, TX: StataCorp LP,  
21. Bougeard G, Renaux-Petel M, Flaman JM, et al. (2015) Revisiting Li-Fraumeni Syndrome From TP53 
Mutation Carriers. J Clin Oncol 33(21): 2345-52 DOI 10.1200/JCO.2014.59.5728 
22. Evans DG, Kesavan N, Lim Y, et al. (2014) MRI breast screening in high-risk women: cancer 
detection and survival analysis. Breast Cancer Res Treat 145(3): 663-72 DOI 10.1007/s10549-014-2931-9 
23. Evans DG, Lennard F, Pointon LJ, et al. (2009) Eligibility for magnetic resonance imaging screening in 
the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in 
the MARIBS Study. Cancer Epidemiol Biomarkers Prev 18(7): 2123-31 DOI 10.1158/1055-9965.EPI-09-0138 
 22 
 
24. Hoang HLT, Ensor K, Rosen G, Leon Pachter H, Raccuia JS (2014) Prognostic Factors and Survival in 
Patients Treated Surgically for Recurrent Metastatic Uterine Leiomyosarcoma. International Journal of Surgical 
Oncology 2014: 8 DOI 10.1155/2014/919323 
25. Schomas DA, Laack NNI, Rao RD, et al. (2009) Intracranial low-grade gliomas in adults: 30-year 
experience with long-term follow-up at Mayo Clinic. Neuro-Oncology 11(4): 437-45 DOI 10.1215/15228517-
2008-102 
26. Pepper C, Thomas A, Hoy T, et al. (2003) Leukemic and non-leukemic lymphocytes from patients with 
Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to 
conventional chemotherapeutic drugs but not flavopiridol. Cell cycle (Georgetown, Tex) 2(1): 53-8  
27.  Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F, Brugiéres L, 
Vargas FR, Brentani RR, Ashton-Prolla P, Landi S, Tavtigian SV, Hainaut P, Achatz MI. (2010) Detailed 
haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: 
evidence for a founder effect. Hum Mutat; 31(2):143-50. . doi: 10.1002/humu.21151. 
28. Saifudeen Z, Dipp S, El-Dahr SS (2002) A role for p53 in terminal epithelial cell differentiation. J Clin 
Invest 109(8): 1021-30 DOI 10.1172/JCI13972 
29. Saifudeen Z, Dipp S, Stefkova J, Yao X, Lookabaugh S, El-Dahr SS (2009) p53 regulates metanephric 
development. J Am Soc Nephrol 20(11): 2328-37 DOI 10.1681/ASN.2008121224 
 
  
 23 
 
Baseline Results from the UK SIGNIFY Study: A Whole-Body MRI 
Screening Study in TP53 Mutation Carriers and Matched Controls 
Online Only Material 
eTable 1: MR Imaging Protocol 
eTable 2: Details of Incidental Findings and Follow up Investigations 
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eTable 6: MR Imaging Protocol 
 
T1-weighted 
gradient echo 
Fat-suppressed 
T2-weighted 
HASTE 
DWIBS 
Whole body 
diffusion 
weighted MR 
imaging with 
background 
signal 
suppression 
(Free breathing) 
T1-weighted 
VIBE DIXON 
 
Coverage 
From vertex to 
feet 
From vertex to 
feet 
From vertex to feet 
 
From vertex 
to feet 
No of slice partitions 30 30 
30 image sections 
per stack 
52 
Technique Breath-hold Breath-hold Free-breathing Breath-hold 
Orientation Axial Axial Axial Coronal 
Field of View (cm) 38 -40 38-40 38-40 38-40 
Matrix Size 150 x 256 150 x 256 150 x 256 192 x 192 
TR 386 1400 14000 7 
TE 4.8 93 72 2.38 & 4.76 
Echo-planar imaging 
factor 
  150  
Parallel imaging factor 2 2 2 3 
 25 
 
No. of signals 
averaged 
1 1 4 1 
Section thickness 
(mm) 
8 8 8 5 
Direction of motion 
probing gradients 
None None 3 scan trace None 
Receiver bandwidth 330 475 1800 490 
Fat Suppression ** None SPAIR 
STIR (T1 = 180 
ms) 
None 
b-values (s/mm
2
) Not applicable Not applicable 
Typically 50 and 
800-1000 
Not applicable 
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eTable 7: Details of Incidental Findings and Follow up Investigations 
Gender Age Control/C
arrier 
MRI abnormality Investigations Outcome 
M 29 Carrier Maxillary sinusitis 
Left leg: multiple high signals in bone 
Right humerus: high T2 signal 
Right leg:?deposits 
Repeat WB MRI Pending 
M 29 Carrier Left lower lobe lung lesion probably 
infective 
Chest X-ray Chest infection 
M 49 Carrier Thyroid nodule Thyroid Ultrasound Benign 
F 51 Carrier Abdominal wall lesion, suspicious of 
sarcoma 
Liver nodule 
US guided biopsy 
Liver US 
Myxosarcoma 
Benign 
F 48 Carrier Ovarian Cysts 
Pericardial Cyst 
CA-125 & TVUS 
None until symptomatic 
Normal 
Sarcoma 
F 48 Carrier 5mm lung nodule Contrast enhanced CT 
chest 
Lesion resolved 
M 41 Carrier Left ureteric abnormality and atrophic L 
kidney 
Renal function (serum 
creatinine and estimated 
GFR) 
Normal 
M 40 Carrier Posterior left ilium lesion Dedicated pelvic MRI x 5 
CT plus CT guided 
biopsy 
No evidence of 
osteosarcoma on 
biopsy 
F 21 Carrier 1.8cm well circumscribed lesion segment 7 
of liver 
Indeterminate lesion on upper pole of right 
kidney 3.4 cm 
Contrast MRI liver and 
kidney 
Partial nephrectomy and 
partial hepatectomy 
Liver and kidney 
EAML 
F 58 Carrier 12mm angiomyolipoma in right kidney 
Possible fatty lesion in liver 
Liver MRI x 2 
Renal MRI x 2 + US 
Continuing 
surveillance 
F 33 Carrier Right temporal lobe cyst MRI brain Astrocytoma 
F 34 Carrier Right ovarian cyst TVUS 
CA-125 x2 
Cyst resolved 
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F 52 Carrier Lung lower lobe pleurally based lung lesion 
Small lesion in right lobe of liver 
Cystic lesion right side of vagina 
Chest CT 
PET-CT x2 
Liver/pelvic MRI 
Continuing 
surveillance for 
lung lesion 
Haemorrhagic cyst 
of liver 
Vaginal Gartner 
duct cyst 
F 53 Carrier 4.5 x 2.8cm cyst behind right knee  Lower leg US x 2,  
MRI & CT 
Benign 
M 43 Carrier Non-specific signal changes around 
sacroiliac joint 
Pelvic MRI Sacro-iliitis, 
referred to 
rheumatologist 
F 45 Carrier Large right renal mass 
Uterine fibroids 
Left ovary cyst 
 
Abdominal CT 
Pelvic MRI 
Right nephrectomy, TAH 
and left salpingo-
oophorectomy 
Chromophobe renal 
cell carcinoma 
Benign renal 
angiomyolipoma 
Uterine 
leiomyosarcoma 
Uterine leiomyoma 
Benign left ovary 
cyst 
F 25 Control Right ovary cyst 3cm  TVUS Cyst resolved 
F 40 Control Left ovary cyst 3cm TVUS Cyst resolved 
M 43 Control Oedema and fatty change in right 
gastrocnemius muscle 
MRI left lower leg with 
contrast 
Benign AVM or 
haemangioma 
M 40 Control Liver cyst Liver US Pending 
M 41 Control Liver cyst 
Right renal cyst 
US abdomen Haemangioma 
Simple renal cyst 
C37 
F 
39 Control Cyst in right SI joint 
Cystic changes in breasts 
MRI of right SI joint in 6 
months 
Breast US 
Pending 
Breasts- simple 
cysts only 
C40 
M 
51 Control Liver cyst haemangioma 
Renal cyst 
Liver and renal US Haemangioma 
Cortical cysts 
 
AVM = arterio-venous malformation; EAML = Epithelioid angiomyolipoma; GFR= glomerular filtration rate; 
SI = sacro-iliac; TAH = total abdominal hysterectomy; TV = transvaginal; US = ultrasound 
 
